Welcome to our dedicated page for Bristol-Myers Squibb news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb stock.
Bristol Myers Squibb reports news on its pharmaceutical portfolio across oncology, cardiovascular disease and immunology, including regulatory decisions, clinical trial data, commercial access programs and product collaborations. Company updates include Sotyktu (deucravacitinib), a selective TYK2 inhibitor approved in the European Union for active psoriatic arthritis, and Eliquis (apixaban), an oral anticoagulant marketed through the Bristol Myers Squibb-Pfizer alliance.
Recurring developments also cover quarterly financial results, investor conference participation, debt and capital-market activity, research collaborations in cardiovascular and precision-medicine programs, and community initiatives tied to multiple myeloma care. The company’s news flow combines product-specific regulatory milestones with broader disclosures on operating performance and pipeline partnerships.
Bristol Myers Squibb (NYSE: BMY) announced an evolution and expansion of its Standing in the Gaap program to advance more equitable multiple myeloma care. The program will launch one of the largest U.S. multiple myeloma surveys, engaging >1,000 patients, caregivers and providers.
The survey, developed with leading advocacy groups, builds on a decade of activity since 2016, including >50 educational programs, ~5,000 attendees and a digital community of nearly 60,000, to translate lived experience into community-informed action.
Bristol Myers Squibb (NYSE: BMY) reported positive Phase 3 SCOUT-HCM results for Camzyos (mavacamten) in adolescents with symptomatic obstructive hypertrophic cardiomyopathy on March 29, 2026. The trial met its primary endpoint with an LS mean Valsalva LVOT gradient reduction of −48.0 mm Hg at Week 28 (P < 0.0001).
Camzyos showed improvements in resting and post-exercise gradients, maximal LV wall thickness, diastolic function (E/e'), and NYHA class versus placebo; safety was similar to adults with no LVEF <50% observed during 28 weeks.
Bristol Myers Squibb (NYSE: BMY) reported Phase 4 data showing symptom stability when switching adults with schizophrenia from oral atypical antipsychotics to Cobenfy (xanomeline and trospium chloride) over 8 weeks.
Key findings: ~86% completed treatment, no discontinuations for lack of efficacy, mean PANSS changes −4.2 (4-week taper) and −3.1 (2-week taper), 49% experienced ≥1 TEAE with no serious TEAEs, and tolerability consistent with prior EMERGENT trials.
Viz.ai will present three abstracts on Viz HCM, its AI-ECG solution within the Viz Cardio Suite, at ACC.26 (March 28–30, 2026).
Key findings include 11 new real-world HCM diagnoses, 13% progression from AI-positive/phenotype-negative over 2.74 years, and that Viz HCM is the first FDA-cleared AI algorithm for HCM detection from a standard 12-lead ECG. The tool was developed under a multi-year agreement with Bristol Myers Squibb (NYSE: BMY).
insitro expanded its ALS collaboration with Bristol Myers Squibb (NYSE: BMY) by adding two targets, ALS-2 and ALS-3, joining ALS-1 (nominated Dec 2024). insitro will advance an oligonucleotide for ALS-1 while BMY progresses a small molecule; insitro received a $10 million milestone.
Using its Virtual Human™ platform, insitro identified targets linked to TDP-43 mislocalization (~97% of ALS) and showed in iPSC-derived motor neurons rescue of neurite growth and reduction of cryptic exons.
Bristol Myers Squibb (NYSE: BMY) will present new clinical and real-world data for Camzyos (mavacamten) at ACC.26 (March 28–30, 2026). Key findings include positive Phase 3 SCOUT-HCM results in adolescents, multiple real-world studies confirming sustained effectiveness and safety, and up to five years of follow-up data.
Camzyos is approved in more than 60 countries, has been prescribed by over 4,500 HCPs to more than 22,000 U.S. patients, and remains available only through a REMS program because of LVEF/heart-failure risks.
Bristol Myers Squibb (NYSE: BMY) announced U.S. and EU approvals expanding Opdivo (nivolumab) indications for classical Hodgkin lymphoma (cHL) on March 20, 2026. In the U.S., Opdivo+AVD is approved for untreated Stage III/IV cHL in patients ≥12 years. In the EU, Opdivo+brentuximab vedotin is approved for relapsed/refractory cHL in patients 5–30 years after one prior therapy. The U.S. decision was supported by Phase 3 SWOG 1826 showing a 58% reduction in risk of progression or death (HR 0.42). Safety signals include 39% serious adverse reactions and 0.6% fatal reactions in SWOG 1826.
Bristol Myers Squibb (NYSE: BMY) will report first-quarter 2026 results on April 30, 2026. Company executives will discuss results on a conference call beginning at 8:00 a.m. ET and a live audio webcast will be available at investor.bms.com.
Materials will be posted on the Investor Relations site before the call, and a replay will be available approximately three hours after the call concludes.
Contact emails: media@bms.com and investor.relations@bms.com.
Bristol Myers Squibb (NYSE: BMY) announced positive interim Phase 3 results from the SUCCESSOR-2 study of oral mezigdomide combined with carfilzomib and dexamethasone (MeziKd) in relapsed or refractory multiple myeloma. MeziKd showed a statistically significant, clinically meaningful improvement in progression-free survival (PFS) versus carfilzomib and dexamethasone alone.
Safety was consistent with the known profile; patients will continue to be followed for overall survival and long-term safety. Data will be presented at a future medical meeting and shared with health authorities.
Bristol Myers Squibb (NYSE:BMY) announced FDA approval of Sotyktu (deucravacitinib) for adults with active psoriatic arthritis on March 7, 2026. Approval was supported by pivotal POETYK PsA-1 and PsA-2 trials where Sotyktu 6 mg once daily achieved ACR20 rates of 54% vs placebo 34% (PsA-1) and 54% vs placebo 39% (PsA-2) at Week 16. Common adverse reactions include upper respiratory infections, increased CPK, herpes simplex, mouth ulcers, folliculitis, and acne. Warnings include infections, malignancy including lymphomas, rhabdomyolysis, laboratory abnormalities, and potential risks related to JAK inhibition.